Read the latest news and updates from NCATS.

Is this email not displaying correctly?
View it in your browser.

National Center for Advancing Translational Sciences | Catalyzing Innovation
Volume 05 • Issue 05 • May 26, 2016

Director's Message

NCATS Director Christopher P. Austin, M.D.

NCATS accelerates translational science through initiatives that push the boundaries of biomedical research to revolutionize the way we study diseases and discover treatments. I am very excited about a new such signature initiative: NCATS’ Biomedical Data Translator program...


Connect with NCATS


Top Story

Depressed man sitting in chair with head in hands.

Ketamine Metabolite May Fight Depression

NCATS scientists were part of a team that helped identify a chemical byproduct — a metabolite — that is created as the body breaks down ketamine. This metabolite reversed depression-like behaviors in mice without triggering the dissociative and addictive side effects associated with ketamine. Read more >

Facebook logo
Twitter logo

University of New Mexico researcher Richard Larson, M.D., Ph.D., with some of his colleagues.

CTSA Program Supports Streamlined Clinical Trial Recruitment

Researchers at the University of New Mexico Clinical and Translational Science Center recently established the Participant Recruitment Service. Supported through NCATS’ Clinical and Translational Science Awards Program, the goal is to streamline and improve recruitment rates for clinical trials while maintaining patient privacy. Read more >

Twitter logo

An NCATS researcher analyzes data from a high-throughput drug screen.

NCATS Funding Opportunity for Biomedical Data Translator

NCATS launched its Biomedical Data Translator program to accelerate biomedical translation by developing a “data translator” for researchers. Through this program, NCATS will integrate multiple types of existing data sources and reveal potential relationships across the spectrum of data types. Proposals for the architecture and technical feasibility of the translator are due June 1, 2016. Read more >

Facebook logo
Twitter logo

Spheryx, Inc., president and CEO Laura A. Philips, Ph.D., M.B.A.

Spheryx, Inc., President/CEO Talks SBIR-Supported Tech

A recent CEOCFO Magazine article features Spheryx, Inc., president and CEO Laura A. Philips, Ph.D., M.B.A., discussing the company’s innovative approach to analyzing particles suspended in fluids. Supported in part by an NCATS Small Business Innovation Research grant, Spheryx provides technology that enables the pharmaceutical industry to study product stability. Read more >

Facebook logo
Twitter logo

Meet More of NCATS’ Staff

Redonna K. Chandler, Ph.D., is the deputy director of the NCATS Division of Clinical Innovation. Sury Vepa, Ph.D., J.D., is the senior licensing and patenting manager in the Office of Policy, Communications and Strategic Alliances. Learn more about these and other NCATS staff members via NCATS Staff Profiles >

Facebook logo
Twitter logo



Deadline for NIH researchers to submit Pfizer Centers for Therapeutic Innovation (CTI) pre-proposals to their Technology Transfer Offices.


Next deadline for NIH Technology Transfer Offices to submit proposals to the Pfizer CTI program.

Scientist draws chemical structure.

Research Opportunities and Announcements Highlights

More From NCATS

NCATS in the News

like us on Facebook |  follow us on Twitter |  forward to a friend |  watch us on YouTube

National Center for Advancing Translational Sciences
National Institutes of Health
6701 Democracy Boulevard, 9th Floor
Bethesda, MD 20892

For language access assistance, contact
the NCATS Public Information Officer.

Add us to your address book | Unsubscribe
NIH, National Center for Advancing Translational Sciences